Akbari, Parsa
Sosina, Olukayode A. http://orcid.org/0000-0003-2120-0338
Bovijn, Jonas
Landheer, Karl http://orcid.org/0000-0001-5012-3007
Nielsen, Jonas B.
Kim, Minhee
Aykul, Senem http://orcid.org/0000-0001-7250-2913
De, Tanima
Haas, Mary E. http://orcid.org/0000-0002-2816-9268
Hindy, George
Lin, Nan
Dinsmore, Ian R.
Luo, Jonathan Z.
Hectors, Stefanie
Geraghty, Benjamin
Germino, Mary
Panagis, Lampros
Parasoglou, Prodromos
Walls, Johnathon R.
Halasz, Gabor
Atwal, Gurinder S.
Della Gatta, Giusy
Jones, Marcus
LeBlanc, Michelle G.
Still, Christopher D.
Carey, David J.
Giontella, Alice
Orho-Melander, Marju http://orcid.org/0000-0002-3578-2503
Berumen, Jaime http://orcid.org/0000-0001-6707-3317
Kuri-Morales, Pablo
Alegre-Díaz, Jesus http://orcid.org/0000-0001-9390-3871
Torres, Jason M.
Emberson, Jonathan R. http://orcid.org/0000-0001-7792-9422
Collins, Rory
Rader, Daniel J. http://orcid.org/0000-0002-9245-9876
Zambrowicz, Brian http://orcid.org/0000-0001-8831-0406
Murphy, Andrew J. http://orcid.org/0000-0003-4152-4081
Balasubramanian, Suganthi
Overton, John D.
Reid, Jeffrey G. http://orcid.org/0000-0001-8645-4713
Shuldiner, Alan R. http://orcid.org/0000-0001-9921-4305
Cantor, Michael
Abecasis, Goncalo R. http://orcid.org/0000-0003-1509-1825
Ferreira, Manuel A. R. http://orcid.org/0000-0001-9059-1825
Sleeman, Mark W.
Gusarova, Viktoria
Altarejos, Judith
Harris, Charles
Economides, Aris N. http://orcid.org/0000-0002-6508-8942
Idone, Vincent
Karalis, Katia
Della Gatta, Giusy
Mirshahi, Tooraj http://orcid.org/0000-0002-0754-3820
Yancopoulos, George D.
Melander, Olle
Marchini, Jonathan http://orcid.org/0000-0003-0610-8322
Tapia-Conyer, Roberto http://orcid.org/0000-0003-3814-2904
Locke, Adam E. http://orcid.org/0000-0001-6227-198X
Baras, Aris http://orcid.org/0000-0002-6830-3396
Verweij, Niek
Lotta, Luca A. http://orcid.org/0000-0002-2619-5956
,
,
Funding for this research was provided by:
Regeneron Pharmaceuticals
Article History
Received: 8 February 2022
Accepted: 28 July 2022
First Online: 23 August 2022
Competing interests
: Regeneron authors receive salary from and own options and/or stock of the company. G.D.Y is the Chief Scientific Officer and member of the Board of Directors at Regeneron Pharmaceuticals; A.J.M is an Executive Officer of Regeneron Pharmaceuticals. L.A.L., P.A., O.S., M.A.R.F., and A.B. are inventors on provisional patent applications (63/233,258 and 63/274,595), U.S. non-provisional applications (17/549,692, and 17/711,137), and PCT international application (PCT/US21/63150) submitted by RGC relating to <i>INHBE</i> genetics. N.V., O.S., P.A., A.L., A.B., and L.A.L. are inventors on U.S. non-provisional applications (17/740,382), and PCT international application (PCT/US22/28415) submitted by RGC relating to <i>PDE3B</i> genetics. Other co-authors did not declare competing interests.